Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue

Journal of Clinical Oncology

Volumn 15, Issue 2, 1997, Pages 667-673

  Giralt, S ^a   Weber, D ^a   Colome, M ^a   Dimopoulos, M ^a   Mehra, R ^a   Van Besien, K ^a   Gajewski, J ^a   Andersson, B ^a   Khouri, I ^a   Przepiorka, D ^a   von Wolff, B ^a   Delasalle, K ^a   Korbling, M ^a   Seong, D ^a   Alexanian, R ^a   Champlin, R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; THIOTEPA;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MALE; MULTIPLE MYELOMA; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0031026738     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.2.667     Document Type: Article

References (37)

1. Alexanian R, Dimopoulos M: The treatment of multiple myeloma. N Engl J Med 330:484-489, 1994
2. McElwain T, Powles R: High dose intravenous melphalan for plasma cell leukemia and myeloma. Lancet 1:822-823, 1983
3. Barlogie B, Alexanian R, Smallwood L, et al.: Prognostic factors with high dose melphalan for refractory multiple myeloma. Blood 72:2015-2019, 1988
4. Harousseau J, Milpied N, Laporte L, et al.: Double intensive therapy in high-risk multiple myeloma. Blood 79:2827-2833, 1992
5. Fermand J, Chevret S, Ravaud P, et al.: High dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: Results of a phase II trial involving 63 patients. Blood 82:2005-2009, 1993
6. Jagannath S, Vesole D, Glenn L, et al.: Low risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 80:1666-1672, 1992
7. Attal M, Huguet F, Schlaifer D, et al.: Intensive combined therapy for previously untreated aggressive myeloma. Blood 1130-1136, 1992
8. Reiffers J, Marie G, Boiron J: Autologous blood stem cell transplantation in high risk multiple myeloma. Br J Haematol 72:296-297, 1989
9. Anderson K, Andersen J, Soiffer R, et al.: Monoclonal anti-body-purged bone marrow transplantation therapy for multiple myeloma. Blood 82:2568-2576, 1993
10. Attal M, Harousseau J, Stoppa A, et al.: High dose therapy in multiple myeloma: Final analysis of a prospective randomized study of the "Intergroupe Français du Myelome" (IFM-90). Blood 86:124a, 1995 (suppl 1, abstr)
11. Alexanian R, Dimopoulos M, Smith T, et al.: Limited value of myeloablative therapy for late multiple myeloma. Blood 83:512-516, 1994
12. Alexanian R, Dimopoulos M, Hester J, et al.: Early myeloablative therapy for multiple myeloma. Blood 84:4277-4282, 1994
13. Glazier A, Tutschka P, Farmer E, et al.: Graft-versus-host disease in cyclosporine A treated rats after syngeneic and autologous bone marrow reconstitution. J Exp Med 158:1-8, 1983
14. Kennedy J, Vogelsang G, Beveridge R, et al.: Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 11:478-484, 1993
15. Jones R, Vogelsang G, Hess A, et al.: Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1:754-757, 1989
16. Yeager A, Vogelsang G, Jones R, et al.: Induction ot cutaneous graft versus host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute my-eloid leukemia. Blood 11:3031-3035, 1992
17. Barlogie B, Anderson K, Berenson J, et al.: Transplants for multiple myeloma. Bone Marrow Transplant 15:S234-S240, 1995 (Suppl 1)
18. Tricot G, Vesole D, Jagannath S, et al.: Graft-versus-myeloma effect: Proof of principle. Blood 87:1196-1198, 1996
19. + T cells. Blood 86:293a, 1995 (suppl 1, abstr)
20. Tersteppen L, Johnson S, Segers-Nolten I, et al.: Identification and characterization of plasma cells in normal human bone marrow by high resolution flow cytometry. Blood 76:1739-1747, 1990
21. Geller R, Esa A, Beschorner W, et al.: Successful in vitro graft versus tumor effect against Ia-bearing tumor using cyclosporine-induced syngeneic graft-versus-host disease in the rat. Blood 74:1165-1171, 1989
22. Martinez-Maldonado M, Yium J, Suki W, et al.: Renal complications in multiple myeloma: Pathophysiology and some aspects of clinical management. J Chron Dis 24:221-237, 1971
23. Kahan B: Cyclosporine. N Engl J Med 321:1725-1736, 1989
24. Dimopoulos M, Weber D, Kantarjian H, et al.: HyperCVAD for VAD-resistant multiple myeloma. Blood 86:442a, 1995 (suppl 1, abstr)
25. Dimopoulos M, Alexanian R, Przepiorka D, et al.: Thiotepa, busulfan, and cyclophosphamide: A new preparative regimen for autologous or blood stem cell transplantation in high risk multiple myeloma. Blood 82:2324-2328, 1993
26. Task Force on Cyclosporine Monitoring: Critical issues in cyclosporine monitoring: Report of the Task Force on Cyclosporine Monitoring. Clin Chem 33:1269-1288, 1987
27. Bearman S, Appelbaum F, Buckner C, et al.: Regimen related toxicities in patients undergoing bone marrow transplantation. J Clin Oncol 6:1562-1568, 1988
28. Glucksberg H, Storb R, Fefer A, et al.: Clinical manifestations of graft versus host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 18:295-304, 1974
29. Sale G, Lerner K, Barker E, et al.: The skin biopsy in the diagnosis of acute graft-versus-host disease in man. Am J Pathol 89:621-625, 1977
30. Kaplan E, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
31. Gahrton G, Tura S, Ljungman P, et al.: Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 325:1267-1273, 1991
32. Bensinger W, Buckner C, Clift R, et al.: Phase I study of busulfan and cyclophosphamide for allogeneic marrow transplant for patients with multiple myeloma. J Clin Oncol 10:1492-1497, 1992
33. Reece D, Shephard J, Klingemann H, et al.: Treatment of myeloma using intensive therapy and allogeneic bone marrow transplantation. Bone Marrow Transplant 15:117-123, 1995
34. Kennedy J: Induced autologous graft-versus-host disease for the treatment of cancer. Can Treat Rev 20:97-103, 1994
35. Cohen D, Loertscher R, Rubin M, Tilney N, Carpenter C, Strom T: Cyclosporine: A new immunosuppressive agent for organ transplantation. Ann Intern Med 101:667-682, 1984
36. Kaltzmann J: Myeloma-induced immunosuppression a multistep mechanism. J Immunol 121:1405-1415, 1978
37. Kennedy M, Vogelsang G, Jones R: Phase I trial of Interferon gamma to potentiate cyclosporine induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 12:249-257, 1994